TESEO Trial: Shorter Benznidazole Treatment Effective for Chagas Disease
A shorter, once-daily thirty-day course of benznidazol proves just as effective for chronic Chagas disease as the traditional sixty-day, twice-daily regimen while sharply cutting adverse side effects, according to findings published in The Lancet Infectious Diseases by the Teseo study investigators. Funded collaboratively and led by the Barcelona Institute for Global Health (ISGlobal)—a center supported by the “la Caixa” Foundation—alongside the University of Texas at El Paso and CEADES in Bolivia, the Phase 2b clinical trial offers a potential solution to high treatment abandonment rates that have hindered parasite eradication for decades.
- Reduced Duration: A 30-day course of benznidazol matches the efficacy of the standard 60-day regimen against Trypanosoma cruzi infection.
- Fewer Adverse Events: Side effects dropped to 37 percent of patients in the 30-day group, compared to 60 percent under standard care.
- Higher Completion Rates: Eighty-three percent of patients finished the shortened regimen without interruption, up from 60 percent in the standard cohort.
The Trypanosoma cruzi parasite affects over seven million people worldwide, primarily across Latin America, while emerging as a recognized public health concern in the United States, Europe, and Japan. Despite between 30 and 40 percent of infected individuals eventually developing severe cardiac or digestive complications, fewer than 1 percent receive a diagnosis and treatment. Standard protocols established more than fifty years rely on benznidazol and nifurtimox, but toxicity and arduous dosing schedules drive up to 31 percent of patients to abandon therapy prematurely.
To evaluate alternative therapeutic options, the Teseo trial randomized 450 adult patients in Bolivia across six distinct treatment arms. These included three benznidazol schedules spanning 30, 60, and 90 days, alongside three corresponding nifurtimox arms. Evaluating outcomes three years post-treatment, researchers found that the parasite remained undetectable in the blood of 94 percent of participants assigned to the 30-day benznidazol group, closely mirroring the 95 percent efficacy seen in the standard 60-day group. Meanwhile, nifurtimox regimens generally demonstrated lower overall efficacy than benznidazol alternatives.
Adherence and safety metrics heavily favored the shortened course. The thirty-day benznidazol schedule struck an optimal balance between benefit and risk, reducing adverse events while lifting treatment completion to 83 percent.
Despite these promising findings, the research team emphasizes that broader Phase 3 clinical trials remain necessary to confirm safety and efficacy before international treatment guidelines undergo formal revision.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*